Robert Gardner, MD
Neurology · Cape Girardeau, MONPI 1649365917
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $141,878 of the $171,227 with a category attached, or 82.9%. 60 manufacturers reported payments, led by AbbVie at 59.2% of the total. Reporting peaked in 2022 at $52,441 and has fallen 58.1% since, to $21,966 in 2025. Among neurology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,184 payments — averaging $144.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$101K
- Amgen$36K
- Biohaven Pharmaceuticals, Inc.$12K
- Biohaven Pharmaceutical Holding Company Ltd.$3K
- Johnson & Johnson$2K
- Jazz Pharmaceuticals Inc.$2K
- plus $15K from 54 others
What the payments were for
- Consulting fees$6750%
- Speaking & faculty fees$141,87883%
- Travel & lodging$4,3023%
- Food & beverage$23,76914%
- Education$6020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$171,227 in reported general payments places this provider in the 95th percentile of 381 neurology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 120 | $183,300 |
| MayzentSiponimod | 13 | $131,325 |
| Aimovig AutoinjectorErenumab-Aooe | 137 | $112,475 |
| AptiomEslicarbazepine Acetate | 32 | $87,266 |
| BriviactBrivaracetam | 46 | $68,069 |
| XcopriCenobamate | 36 | $60,783 |
| GlatopaGlatiramer Acetate | 11 | $52,134 |
| QuliptaAtogepant | 42 | $47,682 |
| NourianzIstradefylline | 21 | $44,713 |
| OngentysOpicapone | 22 | $27,095 |
| FycompaPerampanel | 18 | $25,817 |
| Nurtec OdtRimegepant Sulfate | 26 | $23,521 |
| ReyvowLasmiditan Succinate | 21 | $16,374 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 20 | $15,753 |
| FelbatolFelbamate | 12 | $11,919 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $101,297 | $230,982162 claims |
| NovartisMayzent | $1,642 | $131,32513 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $339 | $87,26632 claims |
| UCB, Inc.Briviact | $496 | $68,06946 claims |
| SK Life Science, Inc.Xcopri | $437 | $60,78336 claims |
| Neurocrine Biosciences, Inc.Ongentys | $238 | $27,09522 claims |
| Eisai Inc.Fycompa | $965 | $25,81718 claims |
| PfizerNurtec Odt | $392 | $23,52126 claims |
| Lilly USA, LLCReyvow | $530 | $16,37421 claims |
| Upsher-smith Laboratories LLCTopiramate | $33 | $1,927248 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 381 neurology providers in Missouri.
Other neurology in Cape Girardeau
- Robert GardnerCape Girardeau$33K
- David LeeCape Girardeau$22K
- William RosenfeldChesterfield$2.1M
- Barry SingerSaint Louis$1.9M
- Mark TullmanSaint Louis$1.5M
- Curtis SchreiberBolivar$882K
- Robert NaismithSaint Louis$677K
- Daniel MattsonBridgeton$451K
- Siddharth KaulBridgeton$387K
- Barbara GreenChesterfield$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.